12:00 AM
 | 
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ReoPro abciximab: Phase II data; Phase III; marketed as an adjunct in angioplasty

Final data from the company's 1,187-patient TIMI 14 trial showed a 57 percent increase in patients achieving normal flow (TIMI 3 grade) in the blocked artery 90 minutes after treatment with ReoPro plus a reduced...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >